{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:46:37Z","timestamp":1794617197928,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the\u00a0Special\u00a0Fund\u00a0of\u00a0Wu\u00a0Jieping\u00a0Medical Foundation\u00a0for\u00a0Clinical\u00a0Research","award":["320.6750.2022-09-53"],"award-info":[{"award-number":["320.6750.2022-09-53"]}]},{"name":"Xiansheng Clinical Research Special Fund for China International Medical Foundation","award":["Z-2014-06-2301"],"award-info":[{"award-number":["Z-2014-06-2301"]}]},{"name":"Project of the First\nHospital of Jiaxing","award":["No.2022-YB-072"],"award-info":[{"award-number":["No.2022-YB-072"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01753-7","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:16:12Z","timestamp":1736028972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inflammatory markers predict efficacy of immunotherapy in advanced non-small cell lung cancer: a preliminary exploratory study"],"prefix":"10.1007","volume":"16","author":[{"given":"Yingqing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"1753_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1753_CR2","doi-asserted-by":"publisher","first-page":"7836264","DOI":"10.1155\/2021\/7836264","volume":"2021","author":"J Bar","year":"2021","unstructured":"Bar J, Urban D, Amit U, Appel S, Onn A, Margalit O, Beller T, Kuznetsov T, Lawrence Y. Long-term survival of patients with metastatic non-small-cell lung cancer over five decades. J Oncol. 2021;2021:7836264. https:\/\/doi.org\/10.1155\/2021\/7836264.","journal-title":"J Oncol"},{"key":"1753_CR3","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/jco.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol. 2021;39:2339\u201349. https:\/\/doi.org\/10.1200\/jco.21.00174.","journal-title":"J Clin Oncol"},{"key":"1753_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","volume":"9","author":"L Sun","year":"2023","unstructured":"Sun L, Bleiberg B, Hwang WT, Marmarelis ME, Langer CJ, Singh A, Cohen RB, Mamtani R, Aggarwal C. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol. 2023;9:1075\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2023.1891.","journal-title":"JAMA Oncol"},{"key":"1753_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"key":"1753_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/s1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924\u201337. https:\/\/doi.org\/10.1016\/s1470-2045(19)30167-6.","journal-title":"Lancet Oncol"},{"key":"1753_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","volume":"32","author":"AJ Schoenfeld","year":"2021","unstructured":"Schoenfeld AJ, Antonia SJ, Awad MM, et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol. 2021;32:1597\u2013607. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2151.","journal-title":"Ann Oncol"},{"key":"1753_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000398.","journal-title":"J Immunother Cancer"},{"key":"1753_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"key":"1753_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00262-016-1805-x","volume":"65","author":"S Punt","year":"2016","unstructured":"Punt S, Dronkers EA, Welters MJ, et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother CII. 2016;65:393\u2013403. https:\/\/doi.org\/10.1007\/s00262-016-1805-x.","journal-title":"Cancer Immunol Immunother CII"},{"key":"1753_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224\u20135. https:\/\/doi.org\/10.1126\/scitranslmed.3008226.","journal-title":"Sci Transl Med"},{"key":"1753_CR12","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolyt. 2016;3:16011. https:\/\/doi.org\/10.1038\/mto.2016.11.","journal-title":"Mol Ther Oncolyt"},{"key":"1753_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nnano.2017.196","volume":"12","author":"WJM Mulder","year":"2017","unstructured":"Mulder WJM, Gnjatic S. Cancer immunotherapy: from local to global. Nat Nanotechnol. 2017;12:840\u20131. https:\/\/doi.org\/10.1038\/nnano.2017.196.","journal-title":"Nat Nanotechnol"},{"key":"1753_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436\u201344. https:\/\/doi.org\/10.1038\/nature07205.","journal-title":"Nature"},{"key":"1753_CR15","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1084\/jem.20181739","volume":"216","author":"B Ritter","year":"2019","unstructured":"Ritter B, Greten FR. Modulating inflammation for cancer therapy. J Exp Med. 2019;216:1234\u201343. https:\/\/doi.org\/10.1084\/jem.20181739.","journal-title":"J Exp Med"},{"key":"1753_CR16","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/s1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493-503. https:\/\/doi.org\/10.1016\/s1470-2045(14)70263-3.","journal-title":"Lancet Oncol"},{"key":"1753_CR17","doi-asserted-by":"publisher","first-page":"153303382412466","DOI":"10.1177\/15330338241246651","volume":"23","author":"Q Yuan","year":"2024","unstructured":"Yuan Q, Xu C, Wang W, Zhang Q. Predictive value of NLR and PLR in driver-gene-negative advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: a single institutional cohort study. Technol Cancer Res Treat. 2024;23:15330338241246652. https:\/\/doi.org\/10.1177\/15330338241246651.","journal-title":"Technol Cancer Res Treat"},{"key":"1753_CR18","doi-asserted-by":"publisher","first-page":"107327482211489","DOI":"10.1177\/10732748221148912","volume":"30","author":"WAS Ali","year":"2023","unstructured":"Ali WAS, Huang X, Wu Y, et al. Pretreatment serum lactate dehydrogenase and metastases numbers as potential determinants of anti-PD-1 therapy outcome in nasopharyngeal carcinoma. Cancer Control J Moffitt Cancer Center. 2023;30:10732748221148912. https:\/\/doi.org\/10.1177\/10732748221148912.","journal-title":"Cancer Control J Moffitt Cancer Center"},{"key":"1753_CR19","doi-asserted-by":"publisher","first-page":"2280002","DOI":"10.1080\/07853890.2023.2280002","volume":"55","author":"J Cao","year":"2023","unstructured":"Cao J, Chen Q, Bai X, et al. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors. Ann Med. 2023;55:2280002. https:\/\/doi.org\/10.1080\/07853890.2023.2280002.","journal-title":"Ann Med"},{"key":"1753_CR20","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1097\/js9.0000000000000650","volume":"109","author":"W Liu","year":"2023","unstructured":"Liu W, Ren S, Yang L, Xiao Y, Zeng C, Chen C, Wu F, Hu Y. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study. Int J Surg (London, England). 2023;109:3519\u201326. https:\/\/doi.org\/10.1097\/js9.0000000000000650.","journal-title":"Int J Surg (London, England)"},{"key":"1753_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/1751-2980.12225","volume":"16","author":"J Tang","year":"2015","unstructured":"Tang J, Gao X, Zhi M, Zhou HM, Zhang M, Chen HW, Yang QF, Liang ZZ. Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn\u2019s disease with low hs-CRP. J Dig Dis. 2015;16:118\u201324. https:\/\/doi.org\/10.1111\/1751-2980.12225.","journal-title":"J Dig Dis"},{"key":"1753_CR22","first-page":"334","volume":"17","author":"ZA \u00d6zt\u00fcrk","year":"2013","unstructured":"\u00d6zt\u00fcrk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N, Aydinli M, Kadayifci A, Kepekci Y. Could platelet indices be new biomarkers for inflammatory bowel diseases? Eur Rev Med Pharmacol Sci. 2013;17:334\u201341.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1753_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/09537104.2013.821607","volume":"25","author":"A T\u00fcz\u00fcn","year":"2014","unstructured":"T\u00fcz\u00fcn A, Keskin O, Yakut M, Kalkan C, Soykan I. The predictive value of mean platelet volume, plateletcrit and red cell distribution width in the differentiation of autoimmune gastritis patients with and without type I gastric carcinoid tumors. Platelets. 2014;25:363\u20136. https:\/\/doi.org\/10.3109\/09537104.2013.821607.","journal-title":"Platelets"},{"key":"1753_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265758","volume":"17","author":"M Luo","year":"2022","unstructured":"Luo M, Chen Y, Cheng Y, Li N, Qing H. Association between hematocrit and the 30-day mortality of patients with sepsis: a retrospective analysis based on the large-scale clinical database MIMIC-IV. PLoS ONE. 2022;17: e0265758. https:\/\/doi.org\/10.1371\/journal.pone.0265758.","journal-title":"PLoS ONE"},{"key":"1753_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40520-020-01523-1","volume":"33","author":"F He","year":"2021","unstructured":"He F, Zhu HM, Li BY, Li XC, Yang S, Wang Z, Zhang M. Factors predicting the severity of acute pancreatitis in elderly patients. Aging Clin Exp Res. 2021;33:183\u201392. https:\/\/doi.org\/10.1007\/s40520-020-01523-1.","journal-title":"Aging Clin Exp Res"},{"key":"1753_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28:411\u20139. https:\/\/doi.org\/10.1093\/intimm\/dxw019.","journal-title":"Int Immunol"},{"key":"1753_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"key":"1753_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135. https:\/\/doi.org\/10.1038\/nature14404.","journal-title":"Nature"},{"key":"1753_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.cd-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202\u201316. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0283.","journal-title":"Cancer Discov"},{"key":"1753_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6:74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1.","journal-title":"J Immunother Cancer"},{"key":"1753_CR31","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2015.180","volume":"112","author":"PF Ferrucci","year":"2015","unstructured":"Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015;112:1904\u201310. https:\/\/doi.org\/10.1038\/bjc.2015.180.","journal-title":"Br J Cancer"},{"key":"1753_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12885-021-08194-9","volume":"21","author":"KL Ayers","year":"2021","unstructured":"Ayers KL, Ma M, Debussche G, et al. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer. 2021;21:441. https:\/\/doi.org\/10.1186\/s12885-021-08194-9.","journal-title":"BMC Cancer"},{"key":"1753_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.013.","journal-title":"Lung Cancer"},{"key":"1753_CR34","doi-asserted-by":"publisher","first-page":"19673","DOI":"10.1038\/s41598-019-56218-z","volume":"9","author":"R Howard","year":"2019","unstructured":"Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9:19673. https:\/\/doi.org\/10.1038\/s41598-019-56218-z.","journal-title":"Sci Rep"},{"key":"1753_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.4149\/bll_2021_078","volume":"122","author":"R Zahorec","year":"2021","unstructured":"Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122:474\u201388. https:\/\/doi.org\/10.4149\/bll_2021_078.","journal-title":"Bratisl Lek Listy"},{"key":"1753_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1160\/th14-12-1067","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114:449\u201358. https:\/\/doi.org\/10.1160\/th14-12-1067.","journal-title":"Thromb Haemost"},{"key":"1753_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1055\/s-0034-1370767","volume":"40","author":"HA Goubran","year":"2014","unstructured":"Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014;40:296\u2013305. https:\/\/doi.org\/10.1055\/s-0034-1370767.","journal-title":"Semin Thromb Hemost"},{"key":"1753_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cmet.2023.12.020","volume":"36","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Xu X, Zhang D, et al. Targeting Erbin-mitochondria axis in platelets\/megakaryocytes promotes B cell-mediated antitumor immunity. Cell Metab. 2024;36:541-56.e9. https:\/\/doi.org\/10.1016\/j.cmet.2023.12.020.","journal-title":"Cell Metab"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01753-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:37:00Z","timestamp":1736030220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01753-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethical Committee of The First Affiliated Hospital of Jiaxing University and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}